Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications

Tomoko Ichiki, John A. Schirger, Brenda K. Huntley, Frank V. Brozovich, Joseph Maleszewski, Sharon M. Sandberg, S Jeson Sangaralingham, Soon J. Park, John C Jr. Burnett

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Left ventricular assist device (LVAD) support has been used in the treatment of end-stage heart failure (HF), however use of anti-fibrotic co-therapies may improve prognosis. Natriuretic peptides (NPs) possess anti-fibrotic properties through their receptors, GC-A/GC-B/NPR-C. We sought to evaluate cardiac fibrosis and the endogenous NP system in end-stage HF with and without LVAD therapy and to assess the anti-fibrotic actions of the dual GC-A/-B activator CD-NP in vitro. Collagen (Col) protein content was assessed by Picrosirius Red staining and NPs, NP receptors, and Col I mRNA expression were determined by qPCR in LV tissue from patients in end-stage HF (n. = 13), after LVAD support (n. = 5) and in normal subjects (n. = 6). Col I mRNA and protein levels in cardiac fibroblasts (CFs) pretreated with CD-NP were compared to those of BNP or CNP pretreatment. The LV in end-stage HF was characterized by higher Col I mRNA expression and Col protein deposition compared to normal which was sustained after LVAD support. ANP and BNP mRNA expressions were higher while CNP was lower in end-stage HF LV. GC-A expression did not change while GC-B and NPR-C increased compared to normal LV. The changes in NP system expression were not reversed after LVAD support. In vitro, CD-NP reduced Col I production stimulated by TGF-beta 1 greater than BNP or CNP in CFs. We conclude that the failing LV is characterized by increased fibrosis and reduced CNP gene expression. LVAD support did not reverse Col deposition nor restore CNP production, suggesting a therapeutic opportunity for CD-NP.

Original languageEnglish (US)
Pages (from-to)199-205
Number of pages7
JournalJournal of Molecular and Cellular Cardiology
Volume75
DOIs
StatePublished - Oct 1 2014

Fingerprint

Natriuretic Peptides
Guanylate Cyclase
Heart-Assist Devices
Fibrosis
Heart Failure
Collagen
Messenger RNA
Therapeutics
Fibroblasts
Transforming Growth Factor beta1
Proteins
Peptide Receptors
Atrial Natriuretic Factor
Staining and Labeling
Gene Expression

Keywords

  • Fibrosis
  • Heart failure
  • Heart-assist device
  • Natriuretic peptides

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system : Regulation and therapeutic implications. / Ichiki, Tomoko; Schirger, John A.; Huntley, Brenda K.; Brozovich, Frank V.; Maleszewski, Joseph; Sandberg, Sharon M.; Sangaralingham, S Jeson; Park, Soon J.; Burnett, John C Jr.

In: Journal of Molecular and Cellular Cardiology, Vol. 75, 01.10.2014, p. 199-205.

Research output: Contribution to journalArticle

@article{c6401726c2054aeea9bff0bda026d800,
title = "Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications",
abstract = "Left ventricular assist device (LVAD) support has been used in the treatment of end-stage heart failure (HF), however use of anti-fibrotic co-therapies may improve prognosis. Natriuretic peptides (NPs) possess anti-fibrotic properties through their receptors, GC-A/GC-B/NPR-C. We sought to evaluate cardiac fibrosis and the endogenous NP system in end-stage HF with and without LVAD therapy and to assess the anti-fibrotic actions of the dual GC-A/-B activator CD-NP in vitro. Collagen (Col) protein content was assessed by Picrosirius Red staining and NPs, NP receptors, and Col I mRNA expression were determined by qPCR in LV tissue from patients in end-stage HF (n. = 13), after LVAD support (n. = 5) and in normal subjects (n. = 6). Col I mRNA and protein levels in cardiac fibroblasts (CFs) pretreated with CD-NP were compared to those of BNP or CNP pretreatment. The LV in end-stage HF was characterized by higher Col I mRNA expression and Col protein deposition compared to normal which was sustained after LVAD support. ANP and BNP mRNA expressions were higher while CNP was lower in end-stage HF LV. GC-A expression did not change while GC-B and NPR-C increased compared to normal LV. The changes in NP system expression were not reversed after LVAD support. In vitro, CD-NP reduced Col I production stimulated by TGF-beta 1 greater than BNP or CNP in CFs. We conclude that the failing LV is characterized by increased fibrosis and reduced CNP gene expression. LVAD support did not reverse Col deposition nor restore CNP production, suggesting a therapeutic opportunity for CD-NP.",
keywords = "Fibrosis, Heart failure, Heart-assist device, Natriuretic peptides",
author = "Tomoko Ichiki and Schirger, {John A.} and Huntley, {Brenda K.} and Brozovich, {Frank V.} and Joseph Maleszewski and Sandberg, {Sharon M.} and Sangaralingham, {S Jeson} and Park, {Soon J.} and Burnett, {John C Jr.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.yjmcc.2014.08.001",
language = "English (US)",
volume = "75",
pages = "199--205",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system

T2 - Regulation and therapeutic implications

AU - Ichiki, Tomoko

AU - Schirger, John A.

AU - Huntley, Brenda K.

AU - Brozovich, Frank V.

AU - Maleszewski, Joseph

AU - Sandberg, Sharon M.

AU - Sangaralingham, S Jeson

AU - Park, Soon J.

AU - Burnett, John C Jr.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Left ventricular assist device (LVAD) support has been used in the treatment of end-stage heart failure (HF), however use of anti-fibrotic co-therapies may improve prognosis. Natriuretic peptides (NPs) possess anti-fibrotic properties through their receptors, GC-A/GC-B/NPR-C. We sought to evaluate cardiac fibrosis and the endogenous NP system in end-stage HF with and without LVAD therapy and to assess the anti-fibrotic actions of the dual GC-A/-B activator CD-NP in vitro. Collagen (Col) protein content was assessed by Picrosirius Red staining and NPs, NP receptors, and Col I mRNA expression were determined by qPCR in LV tissue from patients in end-stage HF (n. = 13), after LVAD support (n. = 5) and in normal subjects (n. = 6). Col I mRNA and protein levels in cardiac fibroblasts (CFs) pretreated with CD-NP were compared to those of BNP or CNP pretreatment. The LV in end-stage HF was characterized by higher Col I mRNA expression and Col protein deposition compared to normal which was sustained after LVAD support. ANP and BNP mRNA expressions were higher while CNP was lower in end-stage HF LV. GC-A expression did not change while GC-B and NPR-C increased compared to normal LV. The changes in NP system expression were not reversed after LVAD support. In vitro, CD-NP reduced Col I production stimulated by TGF-beta 1 greater than BNP or CNP in CFs. We conclude that the failing LV is characterized by increased fibrosis and reduced CNP gene expression. LVAD support did not reverse Col deposition nor restore CNP production, suggesting a therapeutic opportunity for CD-NP.

AB - Left ventricular assist device (LVAD) support has been used in the treatment of end-stage heart failure (HF), however use of anti-fibrotic co-therapies may improve prognosis. Natriuretic peptides (NPs) possess anti-fibrotic properties through their receptors, GC-A/GC-B/NPR-C. We sought to evaluate cardiac fibrosis and the endogenous NP system in end-stage HF with and without LVAD therapy and to assess the anti-fibrotic actions of the dual GC-A/-B activator CD-NP in vitro. Collagen (Col) protein content was assessed by Picrosirius Red staining and NPs, NP receptors, and Col I mRNA expression were determined by qPCR in LV tissue from patients in end-stage HF (n. = 13), after LVAD support (n. = 5) and in normal subjects (n. = 6). Col I mRNA and protein levels in cardiac fibroblasts (CFs) pretreated with CD-NP were compared to those of BNP or CNP pretreatment. The LV in end-stage HF was characterized by higher Col I mRNA expression and Col protein deposition compared to normal which was sustained after LVAD support. ANP and BNP mRNA expressions were higher while CNP was lower in end-stage HF LV. GC-A expression did not change while GC-B and NPR-C increased compared to normal LV. The changes in NP system expression were not reversed after LVAD support. In vitro, CD-NP reduced Col I production stimulated by TGF-beta 1 greater than BNP or CNP in CFs. We conclude that the failing LV is characterized by increased fibrosis and reduced CNP gene expression. LVAD support did not reverse Col deposition nor restore CNP production, suggesting a therapeutic opportunity for CD-NP.

KW - Fibrosis

KW - Heart failure

KW - Heart-assist device

KW - Natriuretic peptides

UR - http://www.scopus.com/inward/record.url?scp=84922690932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922690932&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2014.08.001

DO - 10.1016/j.yjmcc.2014.08.001

M3 - Article

C2 - 25117468

AN - SCOPUS:84922690932

VL - 75

SP - 199

EP - 205

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -